Literature DB >> 2291040

[Late diagnosis of congenital argininemia during administration of sodium valproate].

D Christmann1, E Hirsch, V Mutschler, M Collard, C Marescaux, J P Colombo.   

Abstract

Congenital hyperargininaemia is a rare condition transmitted as an autosomal dominant trait. Following a one-year free interval, repeated vomiting, psychomotor regression and spastic paraparesis with talipes equinus progressively develop. The diagnosis, confirmed by arginine assays in blood and urine, is probably often missed. We report a case of homozygous arginase deficiency belatedly diagnosed at the age of 18 years, when treatment with sodium valproate (VPA) was instituted. This female patient presented with psychomotor regression since the age of 15 months and with paraparesis since she was 3 years' old. These symptoms rapidly became worse. At the age of 18 years, when she was bed-ridden, she was hospitalized for subintrant tonic seizures. EEG showed generalized, continuous spike-wave discharges at the rate of 3.5 c/s. Treatment with VPA was instituted. Five days later, she went into a state of stupor. Blood ammonia level was elevated at 362 mumol/l. VPA was discontinued, and this was followed by a regression of disturbances of consciousness and by a decrease in arterial ammoniaemia, although the ammonia levels remained high, fluctuating between 40 and 100 mumol/l. Several months after VPA treatment was interrupted, the patient had a second episode of stupor, and her ammoniaemia was 500 mumol/l. Serum amino acid chromatography showed hyperargininaemia at 501 mumol/l (N = 30-150 mumol/l). The diagnosis of arginase deficiency was confirmed by the rise of arginine in red cells, cerebrospinal fluid and urine and, above all, by the finding of a deeply depressed arginase activity in erythrocytes. In all cases of intolerance to VPA, arterial ammoniaemia should be measured after withdrawal of VPA, some time after the acute episode.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291040

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  5 in total

1.  A Case of Hyperargininaemia Presenting at Unusually Low Age.

Authors:  Vanita Lal; Daisy Khera; Garima Gupta; Kuldeep Singh; Praveen Sharma
Journal:  J Clin Diagn Res       Date:  2017-07-01

2.  Neurological deterioration in patients with urea cycle disorders under valproate therapy--a cause for concern.

Authors:  A C Sewell; H J Böhles; J Herwig; M Demirkol
Journal:  Eur J Pediatr       Date:  1995-07       Impact factor: 3.183

Review 3.  Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency.

Authors:  Fernando Scaglia; Brendan Lee
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

4.  Impairment of consciousness induced by valproate treatment following neurosurgical operation.

Authors:  J Landau; M Baulac; G Durand; A de Billy; J Philippon
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

5.  Regulation of metabolic networks by small molecule metabolites.

Authors:  Alex Gutteridge; Minoru Kanehisa; Susumu Goto
Journal:  BMC Bioinformatics       Date:  2007-03-13       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.